Epigenetics of prostate cancer.
- Author:
Xiao-Ming YI
1
;
Wen-Quan ZHOU
Author Information
1. Department of Urology, Nanjing University, School of Medicine/ Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
- Publication Type:Journal Article
- MeSH:
DNA Methylation;
DNA Repair;
Epigenesis, Genetic;
Epigenomics;
Histones;
genetics;
Humans;
Male;
Prostatic Neoplasms;
genetics
- From:
National Journal of Andrology
2010;16(7):635-641
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer is one of the most common malignant tumors in males, and its etiology and pathogenesis remain unclear. Epigenesis is involved in prostate cancer at all stages of the process, and closely related with its growth and metastasis. DNA methylation and histone modification are the most important manifestations of epigenetics in prostate cancer. The mechanisms of carcinogenesis of DNA methylation include whole-genome hypomethylation, aberrant local hypermethylation of promoters and genomic instability. DNA methylation is closely related to the process of prostate cancer, as in DNA damage repair, hormone response, tumor cell invasion/metastasis, cell cycle regulation, and so on. Histone modification causes corresponding changes in chromosome structure and the level of gene transcription, and it may affect the cycle, differentiation and apoptosis of cells, resulting in prostate cancer. Some therapies have been developed targeting the epigenetic changes in prostate cancer, including DNA methyltransferases and histone deacetylase inhibitors, and have achieved certain desirable results.
